News and Announcements
MedAdvisor Completes $8M Oversubscribed Capital Raising
- Published October 19, 2016 3:15PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
19th October 2016, ASX Announcement
Highlights
- MedAdvisor has successfully raised $8 million via an institutional placement (Placement)
- Placement was significantly oversubscribed, with strong support from both existing and new shareholders
- Strong participation from leading Australian institutions and pharmacies, providing further industry validation and recognition
- Funding will be used to complete the acquisition of Healthnotes, strengthening MedAdvisor’s market position and to fuel additional growth initiatives and scale
MedAdvisor Limited (ASX: MDR, the Company), Australia’s leading digital medication management company, is pleased to announce offers have been accepted to raise $8 million via an institutional placement (Placement).
200 million new fully paid ordinary shares, raising a total of $8 million, will be issued at $0.04 per share representing no discount to the 5 day VWAP and a discount of 10% to the last traded price.
To view the full announcement, please click on the button below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
